Does Rivaroxaban Better than Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing PCI?
Archives of Hematology Case Reports and Reviews · 2016
DOI: 10.17352/ahcrr.000003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Hematology Case Reports and Reviews, 2016. Verfasst von M Kara und 4 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Approximately 15% of AF patients have a history of myocardial infarction.Between 5-15% of them will require stenting at some point in their lives with the need for a triple therapy combining an oral anticoagulant, a P2Y12 Inhibitor and aspirin [1][2][3].This combination requires careful evaluation of bleeding risk, stroke risk and the risk of acute coronary syndromes (ACS) to reduce the risk of major hemorrhage [4][5][6].In this context, the PIONEER AF-PCI [7], trial was conducted to evaluate the effectiveness and safety of anticoagulation with rivaroxaban plus either one or two antiplatelet agents.PIONEER AF-PCI included 2.124 patients with non-valvular AF (paroxysmal, persistent or permanent), oral anticoagulation for at least 3 months, and undergoing coronary angioplasty
Zitieren
APA
Kara, M., Aitmokhtar, O., Azaza, A., Seddiki, S., & Harbi, F. (2016). Does Rivaroxaban Better than Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing PCI?. Archives of Hematology Case Reports and Reviews. https://doi.org/10.17352/ahcrr.000003
Vancouver
Kara M, Aitmokhtar O, Azaza A, Seddiki S, Harbi F. Does Rivaroxaban Better than Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing PCI?. Archives of Hematology Case Reports and Reviews. 2016. doi:10.17352/ahcrr.000003
BibTeX
@article{Kara2016,
author = {Kara, M and Aitmokhtar, O and Azaza, A and Seddiki, S and Harbi, F},
title = {Does Rivaroxaban Better than Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing PCI?},
journal = {Archives of Hematology Case Reports and Reviews},
year = {2016},
doi = {10.17352/ahcrr.000003}
}
EUVIMED